Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 202 first-line sotorasib plus chemotherapy versus pembrolizumab plus chemotherapy in PD-L1-negative KRAS G12C advanced nonsquamous NSCLC
NL-OMON61024Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sotorasib, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Amgen. Started Nov 2023; status: recruiting.
02
Drugs
sotorasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61024.